CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.
Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
准确识别抗肿瘤T细胞受体(TCR)是开发基于细胞的癌症免疫疗法面临的重大挑战。我们将来自10个转移性人类肿瘤的55种新抗原特异性TCR克隆型(NeoTCR)映射至其单细胞转录组,识别出CD8+和CD4+新抗原反应性TIL(肿瘤浸润淋巴细胞)的特征。新抗原特异性TIL在肿瘤内呈现肿瘤特异性扩增并具有功能障碍表型,有别于从血液迁入的旁观者细胞和调节性TIL。对73种基于NeoTCR特征预测并进行测试的克隆型开展前瞻性预测和验证,发现一半受试TCR可识别肿瘤抗原或自体肿瘤。NeoTCR特征识别出靶向驱动突变新抗原,以及未突变的病毒或肿瘤相关抗原的TCR,提示存在共同的转移性TIL耗竭程序。NeoTCR特征描绘了转移瘤中TIL的整体图景,使研究者能够完全依据TIL转录状态成功预测TCR,用于癌症免疫治疗。
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic human tumors to their single-cell transcriptomes, we identified signatures of CD8 + and CD4 + neoantigen-reactive tumor-infiltrating lymphocytes (TILs). Neoantigen-specific TILs exhibited tumor-specific expansion with dysfunctional phenotypes, distinct from blood-emigrant bystanders and regulatory TILs.
Prospective prediction and testing of 73 NeoTCR signature-derived clonotypes demonstrated that half of the tested TCRs recognized tumor antigens or autologous tumors. NeoTCR signatures identified TCRs that target driver neoantigens and nonmutated viral or tumor-associated antigens, suggesting a common metastatic TIL exhaustion program. NeoTCR signatures delineate the landscape of TILs across metastatic tumors, enabling successful TCR prediction based purely on TIL transcriptomic states for use in cancer immunotherapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。